Is this your podcast?
Sign up
to track ranks and reviews from Spotify, Apple Podcasts and more
Harborside
The ASCO Post
Predictive and Prognostic Biomarkers in Immunotherapy
Predictive and Prognostic Biomarkers in Immunotherapy Moderator: Vamsi Velcheti, MD, Associate Professor, Director, Thoracic Oncology Program NYU Langone- Laura and Isaac Perlmutter Cancer Center, New York Faculty: Hossein Borghaei, DO, MS, Chief, Thoracic Medical Oncology, Co-Leader, Thoracic Cancer Service Line, Fox Chase Cancer Center, Philadelphia; and David Rimm, MD, PhD, Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology, Yale New Haven Hospital, New Haven
Listen now
Recent Episodes
Citing the recent landmark tumor-agnostic approval of pembrolizumab for patients with microsatellite instability-high (MSI-H)/deficient DNA mismatch repair (dMMR) tumors and the approval of nivolumab/ipilimumab MSI-H/dMMR colorectal cancer, Vamsi Velcheti, MD, and Hossein Borghaei, DO, MS,...
Published 12/18/18
Published 12/18/18
Vamsi Velcheti, MD, and David Rimm, MD, PhD, discuss the recent clinical trials that studied tumor mutation burden (TMB) as a biomarker and the mechanisms behind why tumors with high TMB respond to immunotherapy.
Instructions for CME credit:
If you would like to earn credit, you must take the...
Published 12/18/18
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
